Study Summary
This is an open label, phase I study to assess the safety and efficacy of ADGRE2 CAR-T in patients with relapsed and refractory acute myeloid leukemia
Want to learn more about this trial?
Request More InfoInterventions
ADGRE2 CAR-TBIOLOGICAL
ADGRE2 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Mingming Zhang Zhang | Hangzhou | China |